Concert Pharmaceuticals Inc (CNCE) Stock
CNCE is no longer traded. Concert Pharmaceuticals was delisted from the Nasdaq in March 2023.
Prices on this page are historical; the last trade was March 3, 2023 at $8.37.
Concert Pharmaceuticals stock price history
CNCE final trading statistics
- Final close
- $8.37
- Final trading day
- Mar 3, 2023
- Market cap at delisting
- $401.95M
- Shares outstanding
- 48.02M
- Final 52-week range
- $2.66 – $8.55
- Avg. volume (final 3 mo.)
- 2,255,889
- All-time high (split-adj.)
- $29.05 · Dec 2017
- All-time low (split-adj.)
- $2.69 · Oct 2021
- Return since IPO
- -41.0%
- Beta
- 0.52
- Book value / share
- $2.78
- Price / book
- 3.01
Concert Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $32.6K | -$80.1K | -$2.30 |
| FY2020 | $7.90M | -$74.8M | -$2.40 |
| FY2019 | $1.08M | -$78.2M | -$3.29 |
| FY2018 | $10.51M | -$56.0M | -$2.39 |
| FY2017 | $143.89M | $95.6M | $4.00 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Concert Pharmaceuticals Inc
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
Concert Pharmaceuticals stock FAQ
What happened to Concert Pharmaceuticals stock?
Concert Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $8.37 on March 3, 2023.
Is CNCE stock still trading?
No. CNCE was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.
What was the last price of CNCE stock?
CNCE closed at $8.37 on its final trading day, March 3, 2023, for a market value of about $401.95M.
What were Concert Pharmaceuticals's revenue and earnings in its last full fiscal year?
Concert Pharmaceuticals reported revenue of $32.6K and net income of -$80.1K in fiscal 2021, its last full year as a public company.
When did Concert Pharmaceuticals go public?
Concert Pharmaceuticals Inc stock began trading on February 13, 2014.